Danish pharma major Novo Nordisk (NOV: N) late Thursday announced that the US Food and Drug Administration (FDA) has approved Wegovy HD (once-weekly injectable semaglutide 7.2mg) to reduce excess body weight and maintain weight reduction long-term
Key highlights The shelf life of compounded semaglutide depends on the beyond-use date (BUD) set by the compounding pharmacy
Zhou L, Qu H, Yang L, Shou L
Nausea, headaches, vomiting, and diarrhea are common effects and many questions remain about these drugs, including their long-term impacts on the body
Patients who previously struggled to afford advanced therapies may finally gain consistent treatment options
It's expensive, she says, but adds it's her best option for now.